3 Reasons Sanofi's Stock Could Rise

Shares of the French biopharma Sanofi have underperformed this year. Here are three reasons why this top healthcare name could rebound soon.

Aug 28, 2014 at 12:45PM

After a rocky second quarter, biopharma stocks have rallied in a big way heading toward the end of the year. Gilead Sciences, for example, has shot up 41.5% year to date, with most of this upward movement coming in recent weeks. 

Even so, Sanofi (NYSE: SNY) and some other large-cap pharma stocks have largely failed to participate in this broad-based rally. To illustrate this point, the iShares Nasdaq Biotechnology Index (NASDAQ: IBB) has now risen by close to 22% in 2014, yet Sanofi's shares have posted a mere 5.8% gain thus far.

SNY Chart

SNY data by YCharts.

Sanofi's anemic gains, in comparison to its peers, are likely due to the company reorganizing following a bout with the so-called patent cliff. With most of these patent issues firmly in the past, I believe there are three reasons why Sanofi is now set to return to growth, making it a stock to watch.

Reason No. 1
Sanofi's late-stage pipeline is expected to generate two additional major drug approvals (Toujeo and Lemtrada) within the next 12 months in the U.S. Earlier this month, the Food and Drug Administration approved Cerdelga for the treatment of Gaucher disease type 1, with a commercial launch expected as soon as September. So if all goes as planned on the regulatory front, Sanofi should see a nice bump in top-line growth next year, with experts projecting a forward price-to-earnings ratio somewhere in the low teens. 

Moreover, Sanofi and partner Regeneron (NASDAQ: REGN) recently released strong late-stage top-line results for alirocumab as a potential treatment for hypercholesterolemia; they subsequently announced that regulatory filings in the U.S. and European Union should be completed before year's end. The two companies have set up a thematic conference call to discuss alirocumab with investors on Sept. 2. 

All told, Sanofi appears to be on the fast track to return to growth due, in large part, to a promising clinical pipeline and research collaborations.   

Reason No. 2
Sanofi's Genzyme unit is back to posting double-digit growth as a result of its Fabry disease therapy, Fabrazyme, regaining market share in the U.S. and the highly successful launch of Aubagio for multiple sclerosis last year. Taken together, these two events helped Genzyme sales leap by 29.1%, year over year, in the second quarter. 

Looking ahead, the potential entry of Amicus Therapeutics' (NASDAQ: FOLD) competing Fabry disease treatment could cut into Fabrazyme's growing sales down the line. However, Amicus' oral therapy isn't expected to be used as a broad-based treatment, suggesting that its competitive impact might be limited.

Reason No. 3
In the first half of 2014, Sanofi saw a 33% year-over-year increase in free cash flow. Although the company has not rewarded shareholders by significantly upping either the dividend or share repurchases lately, this notable increase in free cash flow should translate into stable dividend payments and stock buybacks going forward. 

Some of Sanofi's peers have recently suspended repurchasing shares in light of their own patent issues, while other growing biotechs with even stronger cash positions have yet to consider offering a dividend.

So as Sanofi continues to move past the patent cliff and transitions into new products, investors looking for a stable source of income could find this name quite attractive.

Foolish wrap-up
Sanofi's growth strategy is unfolding nicely with the approval of Cerdelga and the monstrous growth of its Genzyme subsidiary. That said, the approval of its long-anticipated multiple sclerosis drug Lemtrada is far from a shoe-in, given that it was rejected by the FDA last year and this resubmission is based solely on hope that a new analysis of old data will somehow sway regulators this time around. Regardless of Lemtrada's ultimate regulatory fate, I believe Sanofi has enough irons in the fire to make it a stock worth putting on your watchlist.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information